BioNexus Gene Lab
BGLC
3 hedge funds and large institutions have $37.3K invested in BioNexus Gene Lab in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.
0.11% less ownership
Funds ownership: 0.99% → 0.88% (-0.11%)
25% less capital invested
Capital invested by funds: $49.8K → $37.3K (-$12.5K)
50% less funds holding
Funds holding: 6 → 3 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$34.8K |
| 2 |
Two Sigma Investments
New York
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$38.7K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$9.17K |
| 3 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$3.02K |
| 4 |
JP Morgan Chase
New York
|
-$162 |
| 5 |
Morgan Stanley
New York
|
-$162 |
BGLC Hedge Fund Activity: Q1 2025 in Review
3 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q1 2025, worth a combined $37.3K — down 25% from $49.8K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BGLC and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $34.8K. The largest seller was UBS Group, exiting entirely with an estimated $38.7K sold.
- 3 institutional investors held BioNexus Gene Lab (BGLC) as of Q1 2025, down from 6 in Q4 2024.
- Funds reported $37.3K of BioNexus Gene Lab stock for Q1 2025, down 25% quarter-over-quarter.
- 2 funds opened new BioNexus Gene Lab positions in Q1 2025 and 5 closed out, a net change of -3 holders.
- The largest BioNexus Gene Lab buyer in Q1 2025 was Citadel Advisors, an estimated $34.8K added.
- The largest BioNexus Gene Lab seller in Q1 2025 was UBS Group, an estimated $38.7K sold.
Based on aggregated 13F filings for Q1 2025.